Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics

被引：0

作者：

Sutera, P. ^{[1
]}

Van der Eecken, K. ^{[2
]}

Kishan, A. U. ^{[3
]}

Hamid, A. ^{[4
]}

Grist, E. ^{[5
]}

Attard, G. ^{[6
]}

Lotan, T. L. ^{[7
]}

Mendes, A. ^{[1
]}

Sweeney, C. ^{[8
]}

Paller, C. ^{[9
]}

Carducci, M. ^{[9
]}

Ross, A. E. ^{[10
]}

Pienta, K. ^{[11
]}

Feng, F. Y. ^{[12
]}

Eisenberger, M. ^{[9
]}

Antonarakis, E. S. ^{[9
]}

Ost, P. ^{[13
]}

Tran, P. T. ^{[11
]}

Deek, M. P. ^{[9
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[2] Univ Ghent, Ghent, Belgium

[3] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Inst Canc Res Royal Marsden, London, England

[6] Inst Canc Res, London, England

[7] Johns Hopkins Sch Med, Dept Pathol & Oncol, Baltimore, MD USA

[8] Dana Farber Inst, Boston, MA USA

[9] Johns Hopkins Med, Baltimore, MD USA

[10] Northwestern Univ, Chicago, IL 60611 USA

[11] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Med Oncol, Baltimore, MD USA

[12] Univ Calif San Francisco, San Francisco, CA 94143 USA

[13] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2596

引用

页码：E294 / E295

页数：2

共 50 条

[31] APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES
Chowdhury, Simon
Bjartell, Anders
Agarwal, Neeraj
Chung, Byung Ha
Given, Robert W.
Pereira de Santana Gomes, Andrea J.
Merseburger, Axel S.
Ozguroglu, Mustafa
Juarez Soto, Alvaro
Uemura, Hirotsugu
Ye, Dingwei
Lopez-Gitlitz, Angela
Londhe, Anil
Mundle, Suneel
Larsen, Julie S.
McCarthy, Sharon
Chi, Kim N.
JOURNAL OF UROLOGY, 2020, 203 : E250 - E250
[32] Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer
Swami, Umang
Velho, Pedro Isaacsson
Nussenzveig, Roberto
Chipman, Jonathan
Santos, Victor Sacristan
Erickson, Stephanie
Dharmaraj, Divya
Alva, Ajjai Shivaram
Vaishampayan, Ulka N.
Esther, John
Hahn, Andrew W.
Maughan, Benjamin Louis
Antonarakis, Emmanuel S.
Agarwal, Neeraj
EUROPEAN UROLOGY, 2020, 78 (05) : 652 - 656
[33] Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Taneja, Samir S.
JOURNAL OF UROLOGY, 2018, 199 (01): : 26 - 28
[34] First-line Therapy for Metastatic Castration-sensitive Prostate Cancer
Lau, Y. H.
Wan, L. Y.
Lam, M. H. C.
HONG KONG JOURNAL OF RADIOLOGY, 2022, 25 (03): : 244 - 245
[35] A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer
Kwon, Daniel Hyuck-Min
Friedlander, Terence
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
[36] Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer
Dandapani, Savita V.
Wong, Jeffrey
Twardowski, Przemyslaw
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (07) : 490 - 496
[37] Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer
Grisay, Guillaume
Lavaud, Pernelle
Fizazi, Karim
CURRENT ONCOLOGY REPORTS, 2024, 26 (05) : 488 - 495
[38] Re: Abiraterone plus Prednisone in Metastatic, Castration-sensitive Prostate Cancer
Faiena, Izak
Salmasi, Amirali
Pantuck, Allan J.
Drakaki, Alexandra
EUROPEAN UROLOGY, 2018, 73 (06) : 981 - 981
[39] Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer
Struss, Werner J.
Black, Peter C.
UROLOGY, 2017, 109 : 1 - 2
[40] Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer
Iwamoto, Hiroaki
Izumi, Kouji
Nakagawa, Ryunosuke
Toriumi, Ren
Aoyama, Shuhei
Kamijima, Taiki
Shimada, Takafumi
Kano, Hiroshi
Makino, Tomoyuki
Naito, Renato
Kadomoto, Suguru
Yaegashi, Hiroshi
Kawaguchi, Shohei
Nohara, Takahiro
Shigehara, Kazuyoshi
Kadono, Yoshifumi
Mizokami, Atsushi
BIOMEDICINES, 2022, 10 (10)

← 1 2 3 4 5 →